linjc16/ctgov huggingface dataset:
The Utility of FDG-PET for Radiation Treatment in NSCLC

Study Overview
=================
Brief Summary
-----------------
Patients planned for radical radiation for NSCLC will undergo conventional CT stimulation and also PET/CT scans for definition of radiation target volumes

Official Title
-----------------
The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)

Conditions
-----------------
Lung Neoplasms, Positron Emission Tomography

Intervention / Treatment
-----------------
* Procedure: PET/CT scan for RT planning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-small cell lung cancer to receive radical radiation Exclusion Criteria: unable to tolerate PET/CT scan

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: PET/CT scan for RT planning|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung neoplasms, positron emissions tomography, radiotherapy planning
Prognostic Value of Endothelial Dysfunction and Coronary Complexity

Study Overview
=================
Brief Summary
-----------------
The investigators test the additional clinical value of the physiological assessment of endothelial function to the morphological assessment of coronary complexity and classical risk score in predicting cardiovascular events.

Detailed Description
-----------------
The investigators enroll consecutive, stable high risk patients for cardiovascular events. The reactive hyperemia peripheral arterial tonometry index (RHI) was measured before coronary angiography and coronary lesions were assessed angiographically by SYNTAX Scoring system. The investigators all subjects and examined the occurrence of cardiovascular events (CV death, non-fatal myocardial infarction and ischemic stroke, unstable angina pectoris, hospitalization for HF, coronary revascularization, or non-fatal aortic and peripheral vascular disease).

Official Title
-----------------
Incremental Significance of Endothelial Function Assessed by Reactive Hyperemia Peripheral Arterial Tonometry to Improve Risk Stratification in High Risk Patients for Cardiovascular Events

Conditions
-----------------
Cardiovascular Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable, high-risk patients with diabetes mellitus, or more than two conventional coronary risk factors, who are referred for coronary angiography because of angina-like chest symptoms. Exclusion Criteria: An ejection fraction < 50% Moderate to severe valvular heart disease Cardiomyopathy Allergy to latex Significant endocrine, hepatic, renal, or inflammatory disease cerebrovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular event | Cardiovascular event consists of cardiovascular death, myocardial infarction, unstable angina, ischemic stroke, coronary revascularization, hospitalization for heart failure, aortic disease and peripheral arterial disease. | Outcome is assessed 1 to 4 years after entry |
Symptom Control 1-year After Circular Stapler Anopexy or Diathermy Excision for Prolapsed Haemorhoids

Study Overview
=================
Brief Summary
-----------------
Background: In an international randomised controlled trial we studied how patient self-reported symptoms improved after either a stapled anopexy operation or a diathermy excision of the haemorrhoids. Methods: The study involved 18 hospitals in Sweden, Denmark and the UK. Two hundred and seven patients were randomised. After exclusion of 27 patients, 90 in both groups were operated and followed one year. Patients provided self-reported symptoms before surgery and after 1 year. A patient diary obtained daily self-reported postoperative pain scores (VAS). Surgeons evaluated the anal anatomy before surgery and after 1 year.

Official Title
-----------------
Symptom Control 1-year After Circular Stapler Anopey or Diathermy Excision for Prolapsed Haemorrhoids: an International Randomsed Trial (the STOPP-trial

Conditions
-----------------
Hemorrhoids

Intervention / Treatment
-----------------
* Procedure: Haemorrhoidectomy a.m. Milligan
* Procedure: Stapled anopexy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Grades III and IV haemorrhoids Exclusion Criteria: Previous operation for high anal fistula or injury to the anal sphincteres

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Haemorrhoidectomy a.m. Milligan for grade 3-4 haemorrhoids | Procedure: Haemorrhoidectomy a.m. Milligan<br>* Surgery<br>|
| Active Comparator: 2<br>Stapled anopexy for grade 3-4 haemorrhoids | Procedure: Stapled anopexy<br>* Surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported frequency of symptoms |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Symptoms, Postoperative pain, Postoperative complications, Milligan, Anopxy
Pituitary Gland Stimulation for Cancer Pain Relief

Study Overview
=================
Brief Summary
-----------------
Patients will undergo an implantation of an extradural pituitary surface electrode in the pituitary fossa. The electrode will be attached to a neurostimulator via which the patient will receive up to 8 (patient requested) stimulations per day.

Official Title
-----------------
Pituitary Gland Stimulation for Cancer Pain Relief

Conditions
-----------------
Oncology Pain

Intervention / Treatment
-----------------
* Device: Pituitary gland stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient In palliative phase of metastatic disease, without options for further systemic treatment or radiotherapy Inadequately controlled pain with standard care Most prominent part of experienced pain is nociceptive Karnofsky Performance Score ≥30 Exclusion Criteria: Not fit for general anesthesia Pregnancy Unfavorable local anatomy for PGS, due to a disease process, or anatomical configuration Clinical signs of posterior pituitary gland disfunction Recent history of alcohol or drug abuse Severe immunodeficiency Need for anticoagulation therapy that cannot be abrogated for surgery Need for subsequent MRI-imaging Cognitive impairments prohibiting full understanding of study and ability to provide informed consent Not able to adequately communicate in Dutch or English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: pituitary stimulation<br>Patients will receive pituitary stimulation as oncology pain treatment. | Device: Pituitary gland stimulation<br>* Pituitary gland stimulation via an surface electrode connected to an external neurostimulator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perceived pain | Numeric Rating Scale (0= no pain, 10=most severe pain) | 4 months | 
| Pain Medication | Morphine Equivalent Doses for background and escape medication | 4 months |
Reducing 30-day Readmissions in Patients With Heart Failure Through Pharmacist Discharge Medication Services

Study Overview
=================
Brief Summary
-----------------
Patients admitted for heart failure that are provided discharge medication services by a pharmacist are less likely to be readmitted within 30 days of primary admission.

Official Title
-----------------
Reducing 30-day Readmissions in Patients With Heart Failure Through Pharmacist Discharge Medication Services

Conditions
-----------------
Heart Failure, Patient Readmission

Intervention / Treatment
-----------------
* Other: Pharmacist discharge medication services


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of heart failure, discharged from any medical service Exclusion Criteria: Unwilling to participate, discharged to nursing/rehab facility, non-English speaking, resident unavailable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Discharge medication services included: Discharge medication reconciliation Identification of medication discrepancies and resolution Medication counseling using health coaching techniques with short term goal setting and follow up phone call | Other: Pharmacist discharge medication services<br>* Included in arm descriptions<br>|
| No Intervention: Comparator<br>Current standard of care provided by nursing staff. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients readmitted to the hospital within 30 days of primary heart failure admission | Fisher's T-test | 30 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who visit the emergency department within 30 days of primary heart failure admission | Fisher's T-test | 30 Days | 
| Number of medication discrepancies identified and the number of medication discrepancies resolved by the pharmacist at discharge. | Fisher's T-test | 30 Days | 
| Number of short term goals set by patient's at discharge and the number of short term goals met by patient's at the 7-10 follow up phone call. | Number of short term goals set will be compared to the number of goals patients achieved, comparison will be calculated by percentage | 30 days |
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

Study Overview
=================
Brief Summary
-----------------
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.

Detailed Description
-----------------
Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.

Official Title
-----------------
A Phase III, Double-Blind, Randomized, Multi-Center, Study of the Safety and Efficacy of Anidulafungin vs. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications.

Conditions
-----------------
Candidiasis

Intervention / Treatment
-----------------
* Drug: Anidulafungin
* Drug: Fluconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Diagnosis of candidemia and/or other forms of invasive candidiasis. Should not have received greater than 48 hours of systemic antifungal therapy. Life expectancy should be greater than 72 hours. Should not have received greater than one week of prophylactic azole therapy 30 days prior to enrollment

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Anidulafungin|nan|
|Drug: Fluconazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Candida blood stream infections, Candida infections, Candidemia, Invasive Candidiasis
Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts

Study Overview
=================
Brief Summary
-----------------
Heroin addiction has emerged as a serious problem with tremendous impacts on the addicts and the society. Since the introduction of opioids substitutive treatment in 2006, more than 30,000 heroin addicts had received treatment, and nearly 12,000 continued on treatment currently. However, an unknown proportion of patients hidden in community remained un-treatment. To motivate the community heroin addicts is thus a challenging task. It is suggested that decision making deficit is core feature which determine outcomes and treatment motivations in patients with addiction disorders. Recently, the state-of-the-art development of epigenetics uncover that environmental modification, via altering level of DNA methylation and gene expression will influence on neurocognitive functioning. Via respondent-driven sampling, this study aims to recruit a representative sample targeting at the hard-to-reach community heroin addicts. The goal of this study is to identify the clinical feature as well as decision making-related neurocognitive deficit in these patients. Moreover, the investigators will explore the interplay of clinical features, DNA methylation and gene expressions on opioids receptor genes. The findings will help to clarify the clinical characteristics of community heroin addicts, to uncover the links between DNA methylation and clinical features of heroin addiction and to develop modifiable treatment targets in the future.

Official Title
-----------------
Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts

Conditions
-----------------
Heroin Addiction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) 20 to 65 of age; 2) meeting DSM-IV criteria of opioids dependence Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| community heroin addicts<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Alternate-Day Buprenorphine Administration. Phase II - 4

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.

Official Title
-----------------
Alternate-Day Buprenorphine Administration. Phase II

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 28 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Crossover Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug use |  |  | 
| Opioid withdrawal |  |  | 
| Opioid agonist effects |  |  | 
| Dose identification |  |  | 
| Pupil diameter |  |  |
Postop Catheterization for Urinary Retention

Study Overview
=================
Brief Summary
-----------------
This study investigates patient's preference and satisfaction with choice of catheterization after surgical urogynecological procedures.

Detailed Description
-----------------
Preoperatively, the enrolled patient receives information about risks and benefits of three ways of bladder catheterization as means of management of postoperative urinary retention. Based on this information, the patient chooses her preferred way of postoperative catheterization in case she experiences acute urinary retention after surgery. After the surgery, those patients requiring catheterization postoperatively evaluate their experience in a postoperative questionnaire.

Official Title
-----------------
Treatment of Postoperative Urinary Retention - WHAT DO WOMEN WANT?

Conditions
-----------------
Urinary Retention

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All female patients who undergo urogynecological surgery procedures at NorthShore University HealthSystem and consent to participate Exclusion Criteria: Patients who cannot read, comprehend, and write in English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction with choice of catheterization method | Assessed through post-operative questionnaire completion | 2 weeks after index procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of complication rates | Comparison of complication rates between intermittent vs. indwelling catheterization: data derived from review of participant medical record | 2 weeks after index procedure |
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

Study Overview
=================
Brief Summary
-----------------
Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations. This study is to evaluate the feasibility and application value by using NGS into identifying genomic mutations in multiple or multifocal primary lung cancers in cell-tumor DNA (ctDNA) from surgical patients

Detailed Description
-----------------
Tumor samples originating from clinically considered multiple or multifocal primary lung cancer patients were available for mutational analysis. DNA and RNA were extracted from fresh tumor tissue or formalin-fixed, paraffin-embedded (FFPE) tissue. A series of cancer-related genomic alterations including single nucleotide variations (SNVs), short insertions and deletions (InDels), copy number variations (CNVs) and gene rearrangements were identified by a comprehensive NGS Panal . High frequency mutations were also identified in blood sample by droplet digital polymerase chain reaction(ddPCR).

Official Title
-----------------
A Prospective Study of Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

Conditions
-----------------
Carcinoma, Non-small-cell Lung Cancer, Thoracic Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have given written informed consent Histopathologically confirmed NSCLC Considered multiple or multifocal primary lung cancer by clinical criteria Exclusion Criteria: Malignant tumor history within the past 5 years Patients who received any treatment prior to resection Insufficient tumor tissue or blood sample

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The detection rate of cancer related genes in multiple primary lung cancer patients by targeted next generation sequencing |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The concordant and discordant frequency of genomic results between tumor tissue and circulating tumor DNA in multiple primary lung cancer patients |  | 18 months | 
| The relationship between disease free survival and genomic results in multiple primary lung cancer patients |  | 5 years | 
| The relationship between overall survival and genomic results in multiple primary lung cancer patients |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Circulating Tumor DNA, Heterogeneous, Multiple primary lung cancer